文献速递浆细胞疾病

年轻无症状单克隆丙种球蛋白病患者的特征与临床病程

Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies.
PubMed 文献 · Br J Haematol · 2026-07-12

该研究连续纳入1237例无症状单克隆丙种球蛋白病患者,其中12.1%年龄<50岁、2%<40岁,旨在描述年轻患者的特征。年轻患者以MGUS为主且女性多见,进展率总体较低,按20/2/20校正基线风险后与老年患者无显著差异。

要点

  • 年轻患者以MGUS多见,<40岁者女性占71%。
  • SMM<50岁2/3/5年进展率4%/6%/12%,低于老年患者的9%/13%/20%。
  • 按20/2/20校正基线风险后,年轻与老年SMM进展无显著差异。

核心结论

  • 年轻无症状单克隆丙种球蛋白病患者的生物学特征与老年患者相似,进展率总体较低,规范随访下并发症风险低。

研究设计与样本

  • 连续纳入1237例无症状单克隆丙种球蛋白病患者,其中12.1%年龄<50岁、2%<40岁,描述性分析其临床特征与病程。

主要发现

  • <50岁患者以MGUS为主且女性多见;<40岁患者中女性占71%,SMM与MGUS各占50%。
  • <50岁患者进展时符合SLiM标准或随访影像发现骨病变,未发生灾难性并发症。
  • SMM<50岁患者2、3、5年进展率分别为4%、6%、12%,老年患者分别为9%、13%、20%。
  • 按20/2/20校正基线风险后,年轻与老年SMM患者进展无显著差异。
  • <50岁MGUS或aWM患者尚无进展;<40岁SMM患者按20/2/20均非高危,中位随访3年无进展事件。

关键数值与推荐

  • SMM<50岁2、3、5年进展率分别为4%、6%、12%,老年患者分别为9%、13%、20%。
  • <40岁SMM患者按20/2/20均非高危,中位随访3年无进展事件。
  • 进展判定涉及SLiM标准(克隆骨髓浆细胞≥60%、受累/未受累血清游离轻链比≥100、MRI<1处局灶病变)或随访影像骨病变。

临床怎么用

  • 年轻无症状单克隆丙种球蛋白病患者可采用规范随访方案,早期检测并低风险随访。
  • 对年轻SMM患者应结合20/2/20基线风险分层评估进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma (SMM) and asymptomatic Waldenström's macroglobulinaemia (aWM) are precursor conditions with variable risk of progression to symptomatic malignancy. We aimed to characterize the asymptomatic monoclonal gammopathies in younger patients among 1237 consecutive patients of which 12.1% were <50 years, while 2% were <40 years. Among patients <50 years, most had MGUS and a female predominance was seen. Of patients <40 years, 71% were females, 50% had SMM and 50% MGUS. Patients <50 progressed with either SLiM criteria (clonal bone marrow plasma cell percentage ≥60% involved:uninvolved serum free light chain ratio ≥100 <1 focal lesions on MRI studies) or bone lesions detected in regular follow-up imaging, without catastrophic complications. For SMM patients <50 years, progression rate to symptomatic disease at 2, 3 and 5 years was 4%, 6% and 12% while for older patients was 9%, 13% and 20%, respectively, but adjusted for baseline risk by 20/2/20, no significant difference emerged. No patient <50 years with MGUS or aWM has yet progressed. Among SMM patients <40 years none was at high risk per 20/2/20, while no progression event occurred after a median follow-up of 3 years. In conclusion, younger patients with asymptomatic monoclonal gammopathies exhibit similar biological features compared to older patients, with generally low progression rates, suggesting early detection and low risk of complications with protocolized follow-up.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Solia E, Theodorakakou F, Malandrakis P, et al. Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies. Br J Haematol. 2026. PMID: 42438285. doi:10.1111/bjh.70667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。